Compagnie Lombard Odier SCmA’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-600
Closed -$2K 624
2020
Q3
$2K Sell
600
-1,360
-69% -$3.88K ﹤0.01% 520
2020
Q2
$7K Sell
1,960
-240
-11% -$866 ﹤0.01% 491
2020
Q1
$8K Sell
2,200
-880
-29% -$2.9K ﹤0.01% 449
2019
Q4
$9K Buy
+3,080
New +$8.01K ﹤0.01% 461

Other funds holding BMY.RT

Compagnie Lombard Odier SCmA's BMY.RT Position: Q4 2020 in Review

Compagnie Lombard Odier SCmA sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 600 shares — an estimated $2K sold.

Compagnie Lombard Odier SCmA first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $9K in Q4 2019. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Compagnie Lombard Odier SCmA reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 600 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $2K.
  • Compagnie Lombard Odier SCmA first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Compagnie Lombard Odier SCmA's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $9K in Q4 2019.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2020, filed 9 Feb 2021.